

The National Disease Registration & Analysis Service (NDRS)

Data Collection for
Recurrences, Progressions & Transformations
v1 March 2025

Welcome to this NDRS training module, which has been designed as a guide to data collection for non-primary pathways.

Background

2008

A commitment made in the 'Cancer Strategy, Improving Outcomes: a Strategy for Cancer' to pilot collection of recurrence data

2011

Announcement that data on recurrence and metastatic cancers should be collected via CWT

2013

COSD launch: Data collection for Primary and Non-Primary cancer (recurrence, progression and transformations)

2015

The 'Cancer Strategy for England, Achieving World Class Cancer Outcomes' Re-enforced the collection of data for recurrent cancers

2024

Launch of the NAoMe National Audit of Metastatic Breast Cancer

First, a little background. In 2008, a commitment was made to pilot the collection of recurrence data. It took a while for this to actually come about but in 2013, COSD was launched to enable collection of data for both primary **and** non-primary cancers. The Cancer strategy for England reinforced the collection of recurrent cancers in 2015 and in 2024 the new national audit of metastatic breast cancers was launched...

Headlines in 2024

2024



Breast
Cancer
Network
Australia

Incomplete data means those living with metastatic breast cancer are also invisible to our health systems and policymakers. Without this figure we cannot advocate, plan or invest to ensure our health systems are meeting the needs of this group.

<https://www.bcna.org.au/latest-news/bcna-news/making-metastatic-breast-cancer-count/>

April



'The First ever publication of secondary breast cancer data met with concerns around absence of critical data'

<https://breastcancer.org/about-us/media/press-releases/first-ever-publication-of-secondary-breast-cancer-data-met-with-concerns-around-absence-of-critical-data/>

April



THE LANCET

Lack of information on numbers of people with metastatic breast cancer

'Even though 20-30% of patients with early breast cancer experience relapse, relapse is not typically recorded by most cancer registries. Therefore, the number of patients living with metastatic breast cancer is not known. Meeting the needs of an under-measured patient population is difficult, as a result, feelings of abandonment and isolation are common among those living with the condition.'

<https://cruk.cambridgecentre.org.uk/news/lancet-commission-breast-cancer-publishes-recommendations-change>

... the only problem is, in too many cases, the data simply isn't there. Not just in the UK ...

Headlines in 2024

October

International Agency for Research on Cancer



'The number of survivors of breast cancer is growing, but **the number of women experiencing metastatic recurrence is unknown** due to a lack of international guidelines for the registration and analysis of recurrence data and support for cancer registries to routinely collect this important data item'
<https://www.iarc.who.int/news-events/collecting-long-term-outcomes-in-population-based-cancer-registry-data-the-case-of-breast-cancer-recurrence/>

May



Kat Southwell METUPUK Blog:
'Since recording of MBC data was made mandatory but never adhered to in 2013, just shy of 130,000 women will have died of metastatic breast cancer'

Kat stated **'We are only counted when we are dead'**
<https://metupuk.org.uk/2024/05/data-collection-for-metastatic-breast-cancer-we-are-only-counted-when-we-are-dead-kat-southwell/>

... but internationally. In her blog for METUPUK Kat Southwell wrote:
Since recording of MBC data was made mandatory (but never adhered to) in 2013, just shy of 130,000 women will have died of metastatic breast cancer.
She also noted: **We are only counted when we are dead.**

Everyone's talking about 'metastatic patients'

Metastatic cancer

- This is where a cancer spreads from where it has started

Metastasis

- The process by which the cancer cells spread

Type

- Local – Cancer has returned in the original tumour site
- Regional – Cancer has spread to regional lymph nodes
- Distant – Cancer that has spread from its original location to other parts of the body it is known as late-stage cancer, Stage 4 cancer or M1 (TNM1)

If a disease changes from an **in-situ** tumour or **non-invasive** lesion (including non-invasive urothelial carcinoma) to a **new primary** invasive lesion, this must be recorded as a **new malignant primary diagnosis of cancer**

The term “metastatic patient” only applies to patients whose primary malignant cancer has spread, either in the form of a recurrence after a cancer-free period, or in the form of spread to other locations for an existing cancer

Definitions of non-primary cancers

Recurrence

*When a patient has been told that they are free of cancer **or** when the cancer can not be detected – **and has subsequently returned***

Progression

*Where a patient is living with a cancer diagnosis and there is a **change** to the **spread** of cancer*

Transformation

*Where there is a **change** in the cancer **type***

A Recurrence indicates the reappearance of a malignant cancer where the patient had previously been told their cancer was no longer detectable.


A Progression diagnosis indicates that their existing cancer has **spread** since it was originally diagnosed.

Haematology, Brain/CNS and Sarcoma are the cancer sites where transformations are mainly diagnosed.

A transformation is recorded where there is a change in the cancer type (morphology) or possibly the ICD10 code (this might occur in Haematology).


These are all types of **non-primary pathway**

Recording a Diagnosis - Primary vs Non-primary




So how do you go about recording these progressions, transformations and recurrences? This graphic is included in the COSD user guide to help you decide. It details the options for recording both primary and non-primary pathways and we're going to go through it step-by-step.

Recording a Diagnosis - Primary vs Non-primary




If a patient presents with a progression or a transformation, you must first determine if the original primary diagnosis is already on your cancer management system. If it is, record any progression or transformation on the original primary pathway.

Recording a Diagnosis - Primary vs Non-primary




But if a patient's original primary pathway is not on your cancer management system, record any progression on a new non-primary pathway. The progression details needed include the ICD10 code of the primary cancer and the type & site of the metastases. Most cancer systems will automatically classify this as a non-primary pathway when a progression diagnosis is selected.

Recording a Diagnosis - Primary vs Non-primary



Similarly, where the patient's original primary pathway is not on your cancer management system, a transformation will need to be recorded on its own non-primary pathway. Details needed will include the date of the transformation and the morphology. Again, classification as a non-primary pathway is automatic in most systems.

Recording a Diagnosis - Primary vs Non-primary



A recurrence is always recorded on a separate non-primary pathway. Details required will include the date of the recurrence diagnosis and the type & site of metastases.

Non-Primary Dataset

All Non-Primary:

- Date of Non-Primary Cancer Diagnosis (Clinically Agreed)
- Original Primary Diagnosis (ICD)
- Metastatic Type
- Metastatic Site
- Palliative Care Specialist Seen Indicator
- Method of Detection

Transformations:

- Morphology (ICD-O-3) Transformation
- Morphology (SNOMED) Transformation
- SNOMED Version Current (Transformation)

The non-primary dataset includes certain basic data items that apply to **all** types of non-primary pathway...

Non-Primary Dataset

All Non-Primary:

- Date of Non-Primary Cancer Diagnosis (Clinically Agreed)
- Original Primary Diagnosis (ICD)
- Metastatic Type
- Metastatic Site
- Palliative Care Specialist Seen Indicator
- Method of Detection

Local

Regional

Distant

Transformations:

- Morphology (ICD-O-3) Transformation
- Morphology (SNOMED) Transformation
- SNOMED Version Current (Transformation)

... which includes the metastatic type, which might be **local** to the original cancer, in the same **region** as the original cancer – this would mean in the regional lymph nodes, or in a **distant** location...

Non-primary dataset

All Non-Primary

- Date of Non-Primary Cancer Diagnosis (Clinically Agreed)
- Original Primary Diagnosis (ICD)
- Metastatic Type
- Metastatic Site
- Palliative Care Specialist Seen Indicator
- Method of Detection

Transformations:

- Morphology (ICD-O-3) Transformation
- Morphology (SNOMED) Transformation
- SNOMED Version Current (Transformation)

Brain

Liver

Unknown Metastatic

Skin

Distant Lymph Node

Bone

Bone Marrow

Regional Lymph Nodes

Other Metastatic Site

... the metastatic site – are the metastatic deposits in specific organs, regional or distant lymph nodes or somewhere else?...

Non-primary dataset

All non-primary

- Date of Non-Primary Cancer Diagnosis (Clinically Agreed)
- Original Primary Diagnosis (ICD)
- Metastatic Type
- Metastatic Site
- Palliative Care Specialist Seen Indicator
- Method of Detection

Transformations

- Morphology (ICD-O-3) Transformation
- Morphology (SNOMED) Transformation
- SNOMED Version Current (Transformation)

Histology

Flow


Molecular

Clinical Exam

... and **how** were the metastases found?


How to identify the non primary patients

Findings of recurrences from these sources are low




Histological identification of non-primary diagnoses is uncommon ...

How to identify the non primary patients




...and not all patients are referred to MDT – we know this but for those that are, are they being reported correctly?

How to identify the non primary patients



Where patients on existing pathways have a subsequent treatment, is this subsequent treatment in response to disease progression and is this progression being recorded?

How to identify the non primary patients



A lot of recurrences and progression will however be confirmed by imaging...

New: Cancer flag in imaging dataset DID's

This is a pilot data item that would be part of the imaging dataset

The **CANCER INDICATION CODE (IMAGING)** flags that a cancer (or the suspicion of a cancer) has been found and requires further investigation.

- 01 Confirmation of primary cancer
- 02 Suspected primary cancer
- 03 Confirmation of cancer recurrence
- 04 Suspected cancer recurrence

Planned for release in 2026 there will be a new data item in the Diagnostic Imaging Dataset – this dataset is submitted direct from radiology systems ... in the meantime, are the imaging reports that indicate progression being flagged and recorded?

How to identify the non primary patients

In 2024

- Top providers (7) – report between 15% and 29% of their overall COSD submissions on non-primary pathways
- 103 (76%) are reporting under 6%



Referral for new or recurrence



Under follow-up (outpatients)



Incidental finding

The top 7 providers in the country reported between 15 and 29% of their diagnoses as non-primary pathways in 2024 ... but ¾ of providers reported less than 6% of their total diagnoses as non-primary pathways.

How to identify the non primary patients

In 2024

- Top providers (7) – report between 15% and 29% of there overall COSD submissions on non-primary pathways
- 103 (76%) are reporting under 6%



Referral for new or recurrence

Cancer Management System

- CWT
- COSD



Under follow-up (outpatients)



Incidental finding

Where a patient is referred in for a suspected new primary cancer that turns out to be a recurrence, these **are** more likely to be recorded because the “suspected cancer” pathway is already in the system...

How to identify the non primary patients

In 2024

- Top providers (7) – report between 15% and 29% of there overall COSD submissions on non-primary pathways
- 103 (76%) are reporting under 6%



Referral for new or recurrence

Cancer Management System

- CWT
- COSD



Under follow-up (outpatients)

Is there a system for notifying either the MDT or your Cancer Services Administration?



Incidental finding

... but what happens where a patient is under out-patient follow up OR there's an incidental finding? Is there a robust system in place to capture **these** non-primary diagnoses?

Tools to support you – Breast and other solid tumour sites

<https://digital.nhs.uk/ndrs/data/cancer-data-training-materials>

National Audit of Metastatic Breast Cancer (NaoMe)

GUIDE TO COLLECTING COSD DATA FOR BREAST CANCER RECURRENCE

What is a recurrence?

A cancer recurrence can be defined as the return of an invasive cancer after treatment and after a period with no apparent cancer. The length of time is not clearly defined. The same cancer may come back where it first started or somewhere else in the body.

A progression differs from recurrence as it relates to a deterioration in known persistent cancer.

A transformation is uncommon in breast cancer and does not apply if the recurrent cancer has an altered grade / molecular marker profile.

Confirming and recording a recurrence

All suspected recurrence diagnoses should be discussed at MDT. If the cancer is located within the breast the MDT should decide if it is a new primary or a recurrence.

Completion of the date of diagnosis of recurrence (CR6500) is particularly important.

If the case is deemed to be a recurrence you must record a new non-primary breast cancer pathway and complete all data items shown on the right to successfully record a recurrence in COSD.

TNM stage is not recorded for a recurrence.

Referral Details - Non-Primary Cancer Pathway

CR0300 Source of Referral

CR7400 Date First Seen
YYYY-MM-DD

CR7410 Organisation Site Identifier (Provider First Seen)
Minimum 5 character code

Diagnosis

CR7100 Original Primary Diagnosis (ICD)

CR6500 Date of Non-Primary Pathway (Clinically Agreed)
Record the date when the cancer recurrence diagnosis was confirmed or agreed. This will normally be one of the three following dates: Pathology, MDT or Other (such as clinical imaging or investigation).
YYYY-MM-DD

CR6520 Metastatic / Recurrence Type
The location of the recurrence:
LOCAL REGIONAL DISTANT

CR1590 Metastatic Site(s)
multiple sites may be selected
LIVER BRAIN LUNG SKIN REGIONAL NODES
DISTANT NODES BONE MARROW OTHER UNKNOWN

CR9000 Method of Detection
not applicable for breast
MONOLOGY CLINICAL EXAM OTHER FLUO MOLECULAR
including histology / cytology including imaging


Palliative Care Specialist Activity

CR1550 Palliative Care Specialist Seen Indicator (Cancer Recurrence)
YES NO NOT KNOWN

Clinical Nurse Specialist

CR2050 Clinical Nurse Specialist Indication Code
Record when contact is made with a site-specific clinical nurse specialist.




Further help and information
Visit digital.nhs.uk/ndrs/data-training-materials for details of the Cancer Outcomes and Services Dataset including the COSD User Guide.



COSD DATA ENTRY CHECKLIST

Refer to the COSD User Guide for further details of any form items.

FIRST RELEASE MARCH 2024

Where recurrences are found, we have a tool to help you with the recording. This downloadable PDF was put together for recurrences in Breast cancer but in truth can be applied to recurrences for **all solid tumour sites** and is available to download from our training modules page

Tools to support you

COSD User Guide (online):

<https://digital.nhs.uk/ndrs/data/data-sets/cosd/cosd-user-guide-v10>

COSD user guide v10.2.8

This guide supports users with the implementation and collection of data as part of the Cancer Outcomes and Services Data set (COSD v10.2.8)

Date Published: 9 November 2023

[View a summary](#)

Current Chapter: **Chapter 1: Introduction**

Next Chapter: **Chapter 2: Introduction - Data collection**

Content

This user guide has been developed to help and support NHS organisations, cancer service teams and clinical staff in recording cancer registrations, submit and report COSD data.

The Cancer Outcomes and Services Data set (COSD) is a complete set of data items, covering all pathologies, diagnoses, treatments, and outcomes. It supports the Cancer Outcomes and Services Data set, covering all pathologies, diagnoses, treatments, and outcomes. It supports the Cancer Outcomes and Services Data set, covering all pathologies, diagnoses, treatments, and outcomes. It supports the Cancer Outcomes and Services Data set, covering all pathologies, diagnoses, treatments, and outcomes.

Additional support is available in the [COSD user guide](#). This user guide is a new version. Training materials have been created and are now published in the COSD guidance to help NHS organisations and clinical staff using the new releases and go live smoothly.

Please use the National Disease Registration Service to help you in NHS England and submit data from the NHS about cancer, new diagnoses and congenital anomalies in England.

Last update: 20 March 2023 12:00pm

Next Chapter: **Chapter 2: Introduction - Data collection**

1	COSD user guide v10.2.8	10	COSD - Chapter 10: Pathology	26	The appendix - General Service Summary
2	Introduction	11	COSD - Chapter 11: Diagnosis	27	The appendix - Colorectal Cancer
3	Collecting and submitting COSD data	12	COSD - Chapter 12: Treatment	28	The appendix - Colorectal Cancer and Bowel Adenoma (CIS)
4	Getting the most from COSD data	13	COSD - Chapter 13: Outcome	29	The appendix - Colorectal Cancer and Bowel Adenoma (CIS) - Clinical Audit
5	How to use COSD data	14	COSD - Chapter 14: Pathology	30	The appendix - Colorectal Cancer and Bowel Adenoma (CIS) - Clinical Audit
6	How to use COSD data	15	COSD - Chapter 15: Pathology	31	The appendix - Head and Neck
7	How to use COSD data	16	COSD - Chapter 16: Pathology	32	The appendix - Liver and Intestine
8	How to use COSD data	17	COSD - Chapter 17: Pathology	33	The appendix - Lung
9	How to use COSD data	18	COSD - Chapter 18: Pathology	34	The appendix - Prostate
10	How to use COSD data	19	COSD - Chapter 19: Pathology	35	The appendix - Skin
11	How to use COSD data	20	COSD - Chapter 20: Pathology	36	The appendix - Upper GI
12	How to use COSD data	21	COSD - Chapter 21: Pathology	37	The appendix - Uterine
13	How to use COSD data	22	COSD - Chapter 22: Pathology	38	The appendix - Breast
14	How to use COSD data	23	COSD - Chapter 23: Pathology	39	The appendix - Ovarian
15	How to use COSD data	24	COSD - Chapter 24: Pathology	40	The appendix - Cervical
16	How to use COSD data	25	COSD - Chapter 25: Pathology	41	The appendix - Endometrial
17	How to use COSD data	26	COSD - Chapter 26: Pathology	42	The appendix - Oesophagus
18	How to use COSD data	27	COSD - Chapter 27: Pathology	43	The appendix - Pancreas
19	How to use COSD data	28	COSD - Chapter 28: Pathology	44	The appendix - Stomach
20	How to use COSD data	29	COSD - Chapter 29: Pathology	45	The appendix - Testis
21	How to use COSD data	30	COSD - Chapter 30: Pathology	46	The appendix - Uterine
22	How to use COSD data	31	COSD - Chapter 31: Pathology	47	The appendix - Vagina
23	How to use COSD data	32	COSD - Chapter 32: Pathology	48	The appendix - Vulva
24	How to use COSD data	33	COSD - Chapter 33: Pathology	49	The appendix - Penis
25	How to use COSD data	34	COSD - Chapter 34: Pathology	50	The appendix - Testis
26	How to use COSD data	35	COSD - Chapter 35: Pathology	51	The appendix - Prostate
27	How to use COSD data	36	COSD - Chapter 36: Pathology	52	The appendix - Uterine
28	How to use COSD data	37	COSD - Chapter 37: Pathology	53	The appendix - Ovarian
29	How to use COSD data	38	COSD - Chapter 38: Pathology	54	The appendix - Cervical
30	How to use COSD data	39	COSD - Chapter 39: Pathology	55	The appendix - Endometrial
31	How to use COSD data	40	COSD - Chapter 40: Pathology	56	The appendix - Oesophagus

There's also help available in the COSD guidance...

Tools to support you

COSD User Guide (online):

<https://digital.nhs.uk/ndrs/data/data-sets/cosd/cosd-user-guide-v10>



Content

The user guide has been developed to help and support ICT specialists, senior service teams and clinical staff in secondary care organisations, submit and report COSD data. The Cancer Outcomes and Services Data set (COSD) is a collection of data items, covering all pathways, diagnosis, treatment, and outcomes. It will have a Core section where most data items are applicable to most pathways and diagnosis, and then 17 data specific data sections, covering specific cancer related data items. Additional support is available in [the COSD support guide](#). This link opens in a new window. Training modules have been created and are now available in the COSD module on the NDRS e-learning and clinical staff using internet, telephone and e-mail accounts.

Please note: The National Disease Registration Service is a part of NHS England and collects data from the NHS about cancer, rare diseases and congenital anomalies in England.
Last update: 20 March 2023 12:00 pm

Next Chapter →
[Introduction - Introduction section](#)


1	COSD user guide v10.2.3	15	COSD - Diagnosis procedures	26	The specific - Cancer service types
2	Introduction	16	COSD - Diagnosis	27	The specific - Colorectal
3	Collecting and submitting COSD data	17	COSD - Patient observation	28	The specific - Colorectal and Cervix HPV self-test
4	Introduction - Introduction section	18	COSD - Primary care diagnosis	29	The specific - Colorectal self-test and Cervix HPV self-test
5	How to record recurrence, progression, and transformations	19	COSD - Administrative Data	30	The specific - Colorectal self-test and Cervix HPV self-test
6	COSD - Introduction	20	COSD - Clinical data	31	The specific - Lung and non-small cell lung cancer
7	COSD - Diagnosis	21	COSD - Clinical data	32	The specific - Lung
8	COSD - Patient observation	22	COSD - Clinical data	33	The specific - Lung and non-small cell lung cancer
9	COSD - Primary care diagnosis	23	COSD - Clinical data	34	The specific - Lung
10	Core - Non primary cancer pathway - Referral	24	COSD - Clinical data	35	The specific - Lung
		25	COSD - Clinical data	36	The specific - Lung

... specifically in sections 5 and 10 which guide administrators through the necessary data items...

Tools to support you

CancerStats:

<https://cancerstats.ndrs.nhs.uk/>



© 2024 National Disease Registration Service (NDRS). All Rights Reserved

13/2/2025

27

...we also have feedback for you – **types** of diagnosis are shown in the Diagnoses dashboard on Cancerstats. If you want to know what your data looks like but don't have a CancerStats account – go to the link shown and sign up...

Tools to support you

Your Regional Data Liaison Manager:

East Midlands & West Yorkshire: **Simon Cairnes** – simon.cairnes@nhs.net

Eastern: **Marianne Mollett** – marianne.mollett@nhs.net

London & South East: **Katrina Sung** – katrina.sung@nhs.net

North West: **Paul Stacey** – p.stacey@nhs.net

Northern & Yorkshire: **Rachael Mann** – rachaelmann@nhs.net

Oxford: **Gemma Feeney** – gemma.feeney@nhs.net

South West: **James Withers** – james.withers@nhs.net

West Midlands: **Gemma Feeney** – gemma.feeney@nhs.net

... and don't forget that NDRS is a resource too! We're here to help.

Wrapping Up

- Over recent years the focus for Trusts has been improving stage data
 - 10 years ago, it was said what you are achieving wouldn't be possible
- We need to show the same commitment with recording recurrences and progressions
- **We don't know how many people are living with metastatic cancer**
- It can take years of data before trends, something meaningful, can be identified
- For every year we don't collect this well, it means another year where this work can't even begin

Trust focus in the last few years has been on improving stage, something that was not, at the time, universally accepted as possible – **but you went and did it anyway**, demonstrating extraordinary commitment to the gathering of accurate data on new primary cancers. We're now being asked to demonstrate that same level of commitment for non-primary pathways because we **genuinely** don't know how many people are living with metastatic cancer. Accumulating a meaningful amount of data takes years: the sooner we start getting the data **in**, the sooner we can **work** with it.

Let's change this statement

Data collection for metastatic breast cancer,

“we are only counted when we are dead”

– Kat Southwell – METUPOK

We can change this.